Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Debt (2016 - 2025)

China Pharma Holdings filings provide 12 years of Non-Current Debt readings, the most recent being $1.3 million for Q2 2025.

  • On a quarterly basis, Non-Current Debt fell 5.93% to $1.3 million in Q2 2025 year-over-year; TTM through Jun 2025 was $1.3 million, a 5.93% decrease, with the full-year FY2024 number at $1.4 million, down 1.47% from a year prior.
  • Non-Current Debt hit $1.3 million in Q2 2025 for China Pharma Holdings, down from $1.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $1.5 million in Q3 2022 to a low of $325072.0 in Q2 2021.
  • Median Non-Current Debt over the past 5 years was $1.4 million (2023), compared with a mean of $1.2 million.
  • Biggest five-year swings in Non-Current Debt: crashed 83.56% in 2021 and later soared 92.5% in 2022.
  • China Pharma Holdings' Non-Current Debt stood at $800000.0 in 2021, then soared by 92.5% to $1.5 million in 2022, then decreased by 8.32% to $1.4 million in 2023, then dropped by 1.47% to $1.4 million in 2024, then dropped by 5.12% to $1.3 million in 2025.
  • The last three reported values for Non-Current Debt were $1.3 million (Q2 2025), $1.4 million (Q1 2025), and $1.4 million (Q4 2024) per Business Quant data.